Reported Earnings • May 24
First quarter 2026 earnings released: kr0.094 loss per share (vs kr0.10 loss in 1Q 2025) First quarter 2026 results: kr0.094 loss per share. Net loss: kr4.33m (loss widened 8.6% from 1Q 2025). Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Fredrik Sjodin was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Nov 07
Bioextrax AB (publ), Annual General Meeting, May 21, 2026 Bioextrax AB (publ), Annual General Meeting, May 21, 2026. 공시 • Oct 25
Bioextrax AB (publ), Annual General Meeting, May 22, 2025 Bioextrax AB (publ), Annual General Meeting, May 22, 2025. Reported Earnings • Aug 21
Second quarter 2024 earnings released: kr0.15 loss per share (vs kr0.22 loss in 2Q 2023) Second quarter 2024 results: kr0.15 loss per share (improved from kr0.22 loss in 2Q 2023). Net loss: kr4.80m (loss narrowed 13% from 2Q 2023). New Risk • Aug 06
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €8.63m (US$9.46m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 44% per year over the past 5 years. Revenue is less than US$1m (kr2.2m revenue, or US$204k). Market cap is less than US$10m (€8.63m market cap, or US$9.46m). Minor Risk Shareholders have been diluted in the past year (35% increase in shares outstanding). Reported Earnings • May 20
First quarter 2024 earnings released: kr0.17 loss per share (vs kr0.17 loss in 1Q 2023) First quarter 2024 results: kr0.17 loss per share (further deteriorated from kr0.17 loss in 1Q 2023). Revenue: kr203.0k (down 81% from 1Q 2023). Net loss: kr4.87m (loss widened 15% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings. Reported Earnings • Feb 18
Full year 2023 earnings released: kr0.81 loss per share (vs kr1.11 loss in FY 2022) Full year 2023 results: kr0.81 loss per share. Revenue: kr3.01m (up 37% from FY 2022). Net loss: kr21.5m (loss widened 15% from FY 2022). Reported Earnings • Nov 19
Third quarter 2023 earnings released: kr0.21 loss per share (vs kr0.30 loss in 3Q 2022) Third quarter 2023 results: kr0.21 loss per share. Net loss: kr5.50m (loss widened 20% from 3Q 2022). Board Change • Sep 01
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 7 non-independent directors. Director Per Hokfelt was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. New Risk • Aug 17
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €9.09m (US$9.91m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 54% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Revenue is less than US$1m (kr2.8m revenue, or US$261k). Market cap is less than US$10m (€9.09m market cap, or US$9.91m). New Risk • Jul 07
New major risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €9.93m (US$10.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 54% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Revenue is less than US$1m (kr2.8m revenue, or US$262k). Minor Risk Market cap is less than US$100m (€9.93m market cap, or US$10.9m). Reported Earnings • Feb 18
Full year 2022 earnings released: kr1.11 loss per share (vs kr0.74 loss in FY 2021) Full year 2022 results: kr1.11 loss per share (further deteriorated from kr0.74 loss in FY 2021). Net loss: kr18.7m (loss widened 77% from FY 2021). Recent Insider Transactions • Jan 17
CTO & Director recently sold €58k worth of stock On the 13th of January, Mohammad H. Ibrahim sold around 200k shares on-market at roughly €0.29 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Reported Earnings • Dec 02
Third quarter 2022 earnings released Third quarter 2022 results: Net loss: kr4.60m (loss widened 80% from 3Q 2021). Board Change • Nov 16
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 7 non-independent directors. Director Per Hokfelt was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. 공시 • Oct 31
Bioextrax AB (publ) to Report Q3, 2022 Results on Nov 29, 2022 Bioextrax AB (publ) announced that they will report Q3, 2022 results on Nov 29, 2022 공시 • Aug 02
Bioextrax AB (publ) to Report Q2, 2022 Results on Aug 31, 2022 Bioextrax AB (publ) announced that they will report Q2, 2022 results on Aug 31, 2022 공시 • May 31
Bioextrax AB (publ), Annual General Meeting, Jun 28, 2022 Bioextrax AB (publ), Annual General Meeting, Jun 28, 2022. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Member of Advisory Board Jan Ravenstijn was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Apr 26
Bioextrax AB (publ) to Report Q1, 2022 Results on May 25, 2022 Bioextrax AB (publ) announced that they will report Q1, 2022 results on May 25, 2022